VBI Vaccines and Sanofi Pasteur partner to increase vaccine stability
Stability is an important part of vaccines, as it impacts the safety and potency of a vaccine, as well as patient access.
Sanofi Pasteur will use VBI’s unique LPV technology and expertise to create a better, more stable formulation for an important Sanofi Pasteur vaccine candidate, as the LPV technology stabilizes vaccine biologics and antigens.
Through this collaboration, Sanofi Pasteur will be able to gain global rights for the use of VBI’s LPV in more Sanofi Pasteur vaccines.
LPV technology uses lipids and a proprietary process to confer the thermostability of biologic or vaccine antigens -- the active ingredient in a vaccine -- up to 40 degrees Celsius.
Further details about the agreement have not yet been disclosed to the general public.
"VBI is proud to be working with Sanofi Pasteur, a significant global vaccine manufacturer, to provide a more stable formulation of one of its key pipeline assets," Jeff Baxter, VBI's president and CEO, said. "Our LPV technology has shown great promise in stabilizing vaccines and biologics of a variety of classes and targets. This collaboration reinforces the potential of our technology."